Polyglutamine disease is now recognized as one of the conformational, amyloid-related diseases. In this disease, polyglutamine expansion in proteins has toxic effects on cells and also results in the formation of aggregates. Polyglutamine aggregate formation is accompanied by conversion of the polyglutamine from a soluble to an insoluble form. In yeast, the efficiency of the aggregate formation is determined by the balance of various parameters, including the length of the polyglutamine tract, the function of Hsp104, and the level of polyglutamine expression. In this study, we found that the co-expression of a long polyglutamine tract, which formed aggregates independently of the function of Hsp104, enhanced the formation of aggregates of a short polyglutamine tract in wild-type cells as well as in ⌬hsp104 mutant cells. Thus, the expression of a long polyglutamine tract would be an additional parameter determining the efficiency of aggregate formation of a short polyglutamine tract. The co-localization of aggregates of long and short polyglutamine tracts suggests the possibility that the enhancement occurs due to the seeding of aggregates of the long polyglutamine tracts.
Expansion of polyglutamine repeats in a protein has now been proved to account for the pathogenesis of at least nine inherited neurodegenerative diseases, including spinobulbar muscular atrophy, Huntington's disease, spinocerebellar ataxia types 1, 2, 3, 6, 7, and 17 (SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and SCA17, respectively), and dentatorubural pallidoluysian atrophy (1) (2) (3) (4) . The expression of polyglutamine repeats is sufficient to cause neurodegeneration or toxicity in model organisms and cell death in cultured cells (5) (6) (7) (8) (9) (10) (11) . The clinical severity and the age of onset of disease symptoms are mainly determined by the length of the polyglutamine in the protein responsible, that is, the longer the polyglutamine, the earlier the onset, and the more severe the disease. Moreover, the deposition of aggregates that contain the expanded polyglutamine is a hallmark of the affected organs and dying cells, and the ability of the expanded polyglutamine to induce these toxic phenomena appears to be inseparably linked with its ability to form aggregates. Thus, the conformational change of the expanded polyglutamine is likely a pathogenic mechanism causing these diseases, although whether the aggregates themselves are pathogenic or not is unknown. Moreover, staining of the brain of Huntington's disease patients with Congo Red suggests that polyglutamine diseases are associated with amyloid fibrils (12) .
Polyglutamine aggregate formation of amyloid-like appearance has been observed in vitro (13) (14) (15) . These studies indicate that aggregate formation is autonomous in vitro in the length-, concentration-, and time-dependent manner of a polyglutamine. However, in vivo, in yeast, polyglutamine aggregate formation requires the function of the molecular chaperone Hsp104, a member of the AAA ϩ superfamily, in addition to the parameters noted above (16, 17) . Upon induction of the expression of these tracts, polyglutamine exists in a soluble form during a lag period and is then converted into aggregates. The soluble lag period is prolonged and the formation of insoluble complexes is slower if the length of the polyglutamine tract is shortened or in ⌬hsp104 mutants.
In vitro, polyglutamine aggregate formation is greatly accelerated, and the soluble lag period is shortened by the addition of preformed fibrils of polyglutamine, whereas in vivo, the soluble lag period is prolonged in ⌬hsp104 mutants (14, 17) . Moreover, prion-like factors with glutamine/asparagine-rich domains were reported to enhance the aggregation of different prion-like factors and of polyglutamine tracts (18, 19) . These results led us to ask if co-expression of a long polyglutamine tract, which is rather Hsp104-independent for aggregate formation, could circumvent the chaperone requirement for polygluatmine aggregate formation of a short polyglutamine tract.
EXPERIMENTAL PROCEDURES
Yeast Strains, Media, and Growth-The wild-type strain W303 (MATa, ade2-1, can1-100, his3 -12,16, leu2-3, 112 , trp1-1, ura3-1; R. Rothstein) and HSP104 deletion strain ⌬hsp104-LEUϩ were kindly provided by S. Lindquist. Cells were cultured in SC-Ura, Trp, SC-RafUra, Trp, or SC-Gal-Ura, Trp (20 g of glucose, raffinose, or galactose, respectively, 5 g of casamino acid, 7 g of yeast nitrogen without amino acids, 20 mg of adenine per liter) at 25°C. For induction, cells were grown to mid-log phase in SC-Raf-Ura, Trp, collected by centrifugation, and transferred to SC-Gal-Ura, Trp.
Plasmid Construction-3HA-Q34 and 3HA-Q80 encoded by low copy plasmids, GPD-3HA-Q34 and GPD-3HA-Q80, respectively, were created as follows. First, YCplac22 plasmid containing GPD promoter (222-GPD) was created by inserting the EcoRI-BamHI fragment of the GPD promoter into the EcoRI-BamHI-cleaved YCplac 22 (20) . Next, GALp-HA-Q80 or GALp-HA-Q34 plasmid 1 was cut with NcoI, blunted, and cut with XbaI, and then the resulting fragment was ligated with the vector portion of 222-GPD, which had been digested with BamHI, blunted, and cut with XbaI. The resulting plasmid was then cut with Asp718 and BamHI, and the resulting vector fragment was ligated with synthetic oligonucleotides (3HA-B, GATCCAACATGTACCCATACGA-TGTTCCTGACTATGCGGGCTATCCCTATGACGTCCCGGACTATGC-AGGATATCCATATGACGTTCCAGATTACGCTG; 3HA-K, GTACCAG-CGTAATCTGGAACGTCATATGGATATCCTGCATAGTCCGGGACG-TCATAGGGATAGCCCGCATAGTCAGGAACATCGTATGGGTACAT-GTTG) . To create high copy plasmids (pTV3HA-Q34, pTV3HA-Q80), the SalI-EcoRI fragment of GPD-3HA-Q34 or GPD-3HA-Q80 was ligated with SalI-EcoRI-cleaved pTV3. Gal-p50Q34 and Gal-p50Q80 were described previously (17) . P50-Q24 encoded by low and high copy plasmids, Gal-p50-Q24 and MGal-p50-Q24, respectively, were obtained as follows. A plasmid, p50-U, which contained a partial deletion of CAG repeats, was accidentally obtained during a cloning using p50-Q80. The KpnI-NheI fragment of p50-U was ligated with the KpnI-SalI fragment and the vector portion of the NheI-SalI fragment from p50-Q80 to create Gal-p50-Q24. Its vector portion was replaced with pRS426 to create MGal-p50-Q24. The expected amino acid sequences of the polyglutamines expressed in this study are as follows: 3HA-Q34, MYPYDVPDYAGYPYDVPDYAGYPYDVPDYAGTQQQK(Q) 31 RDPAS; 3HA-Q80, MYPYDVPDYAGYPYDVPDYAGYPYDVPDYAGTQQ-QK(Q) 77 RDPAS; P50-Q24, MDPYLGRPEQMFHLDGTEKQQQ-K(Q) 21 RDPAS; p50-Q34, MDPYLGRPEQMFHLDGTEKQQQK (Q) 31 RDPAS; and p50-Q80, MDPYLGRPEQMFHLDGTEKQQ-QK(Q) 77 RDPAS. Underlined sequences are epitope tag sequences for anti-p50 antibody. GAL1-promoter-regulated human NF-B1 was created as follows. First the EcoRI fragment of NF-B1 was inserted into the EcoRI site of pRS313-GAL1p to create 313-hp105. Then the NotIStuI and StuI-SalI fragments from 313-hp105 were ligated with the NotI-SalI fragment of pRS316. The epitope tag sequence of p50 was originally derived from that of NF-B1.
Cell Staining and Microscopic Analysis-Immunofluorescence of yeast cells was examined using standard procedures (21) . Briefly, 0.1 M KPO 4 (pH 6.5) was added to the culture, and then cells (2 ϫ 10 7 ) were fixed with 3.6% formaldehyde. Cells were washed with 0.1 M KPO 4 (pH 7.5) and treated to form spheroplasts by incubation in 1 ml of 1 M sorbitol containing 75 g/ml zymolylase-20T and 0.002% 2-mercaptoethanol at 30°C for 1 h. Then 20 l of 10% SDS was added. After 10 min, cells were washed five times with G1T (1% gelatin, 0.5 mg/ml bovine serum albumin, 150 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% Tween 20, 1 mM NaN 3 ), suspended in methanol (Ϫ20°C) for 6 min, and then in acetone (Ϫ20°C) for 30 s, and subsequently incubated in G3T (3% gelatin, 0.5 mg/ml BSA, 150 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% Tween 20, 1 mM NaN 3 ). Cells were incubated with anti-p50 antibody for 1 h and washed with G1T three times. Next, cells were incubated with Texas Red X-conjugated anti-mouse IgG (Molecular Probes) for 30 min, and washed with G1T three times. Cells were then incubated with 0.001ϳ0.002% thioflavin-S (Sigma) in G1T for 10 min and washed twice with G1T. The samples were dissolved in p-phenylenediamine (1 mg/ml in 90% glycerol). For double-labeled immunofluorescence, cells were incubated first with mouse anti-p50 monoclonal antibody and rabbit anti-HA antibody (Medical and Biological Laboratories, Nagoya, Japan), and then with Texas Red X-conjugated goat antimouse IgG and fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (Vector Laboratories) as secondary antibodies. To reduce nonspecific staining of fluorescein isothiocyanate-conjugated antibody, the antibody was preadsorbed to fixed cells prior to use. Polyglutamine aggregate formation was examined by counting the number of cells with coalescent foci in each cell. Non-stained cells and clumps of cells were omitted from the counting for anti-p50 antibody staining. Since a faint background staining was observed for anti-HA antibody staining, cells that were stained more strongly than cells expressing vector were counted as cells with diffusive staining.
Immunoblot Analysis-Preparation of whole cell lysates and SDS-PAGE were performed as described previously (17) . Immunoblot analysis was performed using anti-p50 antibody and anti-HA monoclonal antibody (12CA5) and visualized using ECL-plus reagent (Amersham Biosciences). Monoclonal anti-p50 antibody (KM1819) was a gift from Kyowa Hakko Co. Ltd.
RESULTS

Thioflavin-S Staining of Polyglutamine Aggregates in
Yeast-First, we examined whether polyglutamine aggregates in yeast were stained with thioflavin-S, a compound that binds to amyloid fibrils (22) . In wild-type yeast cells expressing p50-Q80, a portion of MJD disease protein containing expanded polyglutamine repeat with a tag peptide, and polyglutamine aggregates are formed efficiently (17) . These cells were immunostained with anti-tag antibody (anti-p50 antibody) and stained with thioflavin-S (Fig. 1A, panels a-c) . We observed foci by thioflavin-S staining. In the cells expressing vector, foci stained with thiofavin-S were rarely detectable (Fig. 1A , panels e and f). When the localization of the foci was compared with that of foci detected by the immunofluorescence, about half of foci detected by immunofluorescence were stained by thioflavin-S. Most, if not all, foci detected by thioflavin-S were immunostained. Since smaller foci detected by the anti-p50 antibody tended to fail to be stained by thioflavin-S, the sensitivity of thioflavin-S staining for polyglutamine might not be as good as that of the immunofluorescence. The specificity of thiofavin-S staining for polyglutamine aggregates was also confirmed by the absence of foci in cells expressing an irrelevant protein, NF-B1, which contained a p50 peptide sequence at the N terminus of the protein (data not shown).
As polyglutamine aggregate formation depends on Hsp104, the above results suggested that Hsp104 played a role in forming aggregates which were amyloid fibrils. In our previous study (17) , however, we observed that the longer the polyglutamine, the less dependent is its aggregate formation on Hsp104. Thus, the expression of a long polyglutamine tract results in its aggregate formation in the ⌬hsp104 deletion mutants (described as ⌬hsp104 mutants hereafter) to a certain extent, although the aggregation is still less efficient than that in wild-type cells. We then examined whether foci observed in ⌬hsp104 mutants expressing p50-Q80 from a high copy plasmid were stained with thioflavin-S (Fig. 1B) . We detected foci stained with thioflavin-S in the cells, and about 80% of the foci detected by the immunofluorescence were detected as foci by staining with thioflavin-S.
Therefore, these results suggested that 1) polyglutamine expressed in yeast could form aggregates, which were amyloid fibrils, and 2) although Hsp104 was required for efficient formation of polylgutamine aggregates of amyloid fibrils, long polyglutamine could form aggregates of amyloid fibrils in the absence of Hsp104.
Co-expression of Different Polyglutamines in ⌬hsp104 Mutants-Next, we examined the effect of the expression of one polyglutamine on the aggregate formation of another short polyglutamine (p50-Q34) in ⌬hsp104 mutants (Fig. 2) . To distinguish the different polyglutamines, a different tag sequence (3ϫHA) was added at the N terminus of each polyglutamine. 3ϫHA-tagged polyglutamines (3HA-Q80 or 3HA-Q34) in a low or high copy plasmid were expressed constitutively in ⌬hsp104 mutants. As expected, more cells expressing 3HA-Q80 contained polyglutamine aggregates than cells expressing 3HA-Q34 (Fig. 2, A and B) . The expression of p50-Q34 was induced in the same cell, and the aggregate formation of p50-Q34 was examined by immunofluorescent analysis using anti-p50 antibody. Usually, polyglutamine aggregate formation of p50-Q34 in ⌬hsp104 mutants is greatly diminished due to the shortness of its polyglutamine tract and due to its high Hsp104 dependence (16, 17) . The aggregate formation of p50-Q34 was not increased by the expression of 3HA-Q34 from either a low copy plasmid or from a high copy plasmid 1 (Fig. 2C) . However, the co-expression of 3HA-Q80 in a low copy plasmid slightly increased the aggregate formation of p50-Q34 (data not shown). Moreover, when 3HA-Q80 was co-expressed from a high copy plasmid, we observed a significant increase of aggregate formation of p50-Q34 (Fig. 2C) . In contrast, aggregate formation of 3HA-Q80 was not enhanced significantly by the expression of p50-Q34 (Fig. 2D) . Furthermore, when human NF-B1 was expressed in yeast, it was stained diffusely, and its expression pattern was not changed nor did it form foci when co-expressed with 3HA-Q80 (Fig. 3) .
Next, immunoblot analysis was performed to determine the state of the polyglutamine in the ⌬hsp104 mutants. Polyglutamine in a soluble state migrates as a small discrete band, while polyglutamine in the insoluble state migrates as high molecular weight smeared bands in this system (5, 17) . Smeared band formation of 3HA-Q80, which is characteristic of insoluble polyglutamine, was detected by this analysis, whereas the smeared band formation of 3HA-Q34 was much less prominent (Fig. 2F) . When the state of p50-Q34 was examined, an insoluble polyglutamine formation of p50-Q34 was clearly observed when 3HA-Q80 was co-expressed, but not when 3HA-Q34 or vector was co-expressed (Fig. 2E ). The expression level of p50-Q34 was not changed significantly by the co-expression of 3HA-Q80 (Fig. 2E) , indicating that the observed increase of p50-Q34 aggregate formation was not caused by an increase in the level of expression of p50-Q34.
The above results suggested that the aggregates formed by 3HA-Q80 might circumvent the requirement for Hsp104 for the aggregate formation of p50-Q34, perhaps, for example, by providing seeds for p50-Q34 aggregation. Therefore, we examined the localization of the aggregates of 3HA-Q80 and p50-Q34 by double-labeled immunofluorescence analysis (Fig. 2G) . About one-third of aggregate-containing cells contained aggregate(s) of p50-Q34, which were co-localized with aggregate(s) of 3HA-Q80 (Fig. 2, C and G) .
We further investigated the effect of co-expression of a long polyglutamine tract on the aggregate formation of a very short polyglutamine tract. We constructed p50-Q24, a 24-polyglutamine tract with the p50 epitope tag, which did not form aggregates efficiently in wild-type or ⌬hsp104 mutants from a low copy or a high copy plasmid (Fig. 4A) , indicating that its Hsp104-independent aggregating ability was almost lost. When 3HA-Q80 was co-expressed constitutively, a low but significant level of aggregate formation of p50-Q24 was detected in the ⌬hsp104 mutants (Fig. 4A) . When the co-localization of p50-Q24 and 3HA-Q80 was examined by double-labeled fluorescence microscopy, about two-thirds of aggregate-containing cells contained co-localized aggregate(s) (Fig. 4B) . Aggregate formation of p50-Q24 was not enhanced when 3HA-Q34 was co-expressed (data not shown).
Co-expression of Different Polyglutamines in Wild-type Cells-Finally, we examined the effect of co-expression of different polyglutamines in the wild-type cells. When 3HA-Q34 was co-expressed in a low copy plasmid, the aggregate formation of p50-Q34 was increased about 2-fold, and with the coexpression of 3HA-Q80 the aggregate formation of p50-Q34 became much more efficient (Fig. 5A) . When the co-localization was examined, about 20 and 3% of aggregate-containing cells contained aggregates of p50-Q34, which were co-localized with 3HA-Q80 and 3HA-Q34, respectively (Fig. 5A) . When the kinetics of insoluble polyglutamine formation of p50-Q34 were examined by immunoblot analysis after the induction of expression, we found that the soluble lag period became shorter, and the insoluble complex appeared faster when p50-Q34 was co-expressed with 3HA-Q80 than when it was co-expressed with vector alone (Fig. 5B) . panels a and e) . c is a merged image of a and b. d is a phase contrast representation of a-c. B, ⌬hsp104 mutants expressing p50-Q80 from high copy plasmids were immunostained with anti-p50 antibody (panels h and k) and stained with thioflavin-S (panels g and j). i and l are merged images of g and h, and of j and k, respectively. Two representative staining patterns are shown.
DISCUSSION
In this study, we showed that aggregate formation of short polyglutamine, which is otherwise highly dependent on the function of Hsp104, was enhanced by the expression of a long polyglutamine in wild-type cells as well as in ⌬hsp104 mutants.
In vitro, aggregate (or fibril) formation of polyglutaminecontaining proteins is seeded and recruited by preformed polyglutamine fibrils, suggesting that the aggregates form by a process of nucleation-dependent polymerization (14, 15) . In in vitro systems, a defined amount of preformed polyglutamine fibrils is supplied as a seed for a defined amount of soluble polyglutamine. In our in vivo study, long polyglutamine was expressed continuously, and consequently both soluble and insoluble polyglutamines are present together in a dividing cell. Thus, our in vivo experimental system is quite different from the in vitro system. However, the following results obtained here suggested that a process of seeding by aggregates of long polyglutamine might also occur in vivo, and not only in wild-type cells but also in ⌬hsp104 mutants. First, in accordance with the fact that long polyglutamine tracts form more aggregates than short polyglutamine tracts, co-expression of long polyglutamine tracts enhanced the aggregate formation of short polyglutamine tracts, whereas the co-expression of short polyglutamine tracts did not. Second, when the localization of newly formed aggregates of short polyglutamine tracts was examined, significant aggregates were co-localized with aggregates of long polyglutamine tracts. Third, when the kinetics of aggregate formation were examined, the soluble lag time was shortened by the co-expression of a long polyglutamine tract. This shortening of the lag time is one characteristic of the nucleated growth pathway. Moreover, the finding that polyglutamine aggregates in wild-type cells as well as in ⌬hsp104 mutants were stained with thioflavin-S suggested that they are amyloid fibrils and that the amyloid fibrils might serve as a seed.
Although the co-localization of some aggregates supports the idea that the enhancement of aggregate formation occurs through seeding, there was still a portion of aggregates for which the co-localization was not observed. One reason for this may be that aggregates of 3HA-Q80 that might serve as a seed may have been too small to be detected by our immunofluorescent analysis. Another reason may be that enhancement by 3HA-Q80 may be indirect: aggregates of 3HA-Q80 might serve as a seed for some cellular polyglutamine-containing proteins, and aggregates of these proteins might serve as seeds for the aggregate formation of p50-Q34. Alternatively, we can not exclude the possibility that the seeding may not be the only mechanism to enhance p50-Q34 aggregate formation by the expression of 3HA-Q80. There may be inhibitory factors for aggregate formation for p50-Q34, whose inhibitory activity is suppressed by the expression of 3HA-Q80, as has been proposed based on yeast prion studies (18, 19) .
In vivo, in yeast, Hsp104 is required for transition from soluble to insoluble polyglutamine, depending on the length of the polyglutamine tract and/or on the level of expression (16, 17) . As the requirement of Hsp104 for aggregate formation of short polyglutamine was circumvented by the expression of long polyglutamine, this result also suggests that one role of Hsp104 might be facilitating a seed (or nucleus) formation of polyglutamine aggregates by inducing its conformational change. Once the seeds are supplied or created, Hsp104 might not be required for further extension of the aggregates, and soluble polyglutamine might be recruited by preexisiting aggregates and change its conformation, as proposed based on the self-aggregation property of polyglutamine in vitro (14, 15) . Indeed, p50-Q24, a very short 24-mer polyglutamine tract, which did not form aggregates efficiently even when expressed from a high copy plasmid in wild-type cells due to the shortness of its polyglutamine tract, could form more aggregates when the long polyglutamine was co-expressed in ⌬hsp104 mutants. Another role postulated for Hsp104 based on recent yeast prion studies is that Hsp104 may disaggregate preformed fibrils or aggregates to produce a new seed (23) . At present, we cannot rule out the possibility that Hsp104 plays such a role in polyglutamine aggregate formation.
Both chaperone-dependent and -independent aggregate formation or conformational change of polyglutamine might occur in yeast as well as in mammalian systems. Recently, VCP/p97, a member of the AAA ϩ superfamily, which shares common structural motifs with Hsp104, was isolated as a polyglutamine binding protein (24) . Moreover, mutations of one allele of VCP prevented the neurodegeneration caused by polyglutamine expression in a Drosophila model (25) . Considering the pathogenesis of polyglutamine diseases, non-pathogenic short polyglutamine-containing proteins may not usually change their conformation or form aggregates, and their aggregate formation may be highly dependent on molecular chaperone(s). However, the appearance of a long polyglutamine tract in a disease protein may cause chaperone-independent aggregate formation and may induce the aggregate formation of other polyglutamine-containing proteins, which is otherwise highly dependent on molecular chaperones. As there is a polyglutamine tract length-dependent hierarchy of aggregate formation, once such a protein is induced to form aggregates, it may then be able to assist in making other polyglutamine tract-containing proteins form aggregates. Thus, a chain reaction of aggregate formation, or possibly amyloid formation, might occur. Indeed, it was reported that several transcription factors containing a polyglutamine-rich motif were recruited by polyglutamine aggregates and that their activities were consequently inhibited (7, 12, 26 -30) . Accordingly, molecular chaperone(s) may play an important role in the pathogenesis of polyglutamine diseases and may be a therapeutic target for such diseases.
